Format

Send to

Choose Destination
See comment in PubMed Commons below
J Neuroimmunol. 2010 Jun;223(1-2):138-40. doi: 10.1016/j.jneuroim.2010.03.022. Epub 2010 Apr 24.

The serum and cerebrospinal fluid pharmacokinetics of anakinra after intravenous administration to non-human primates.

Author information

1
The Children's Hospital of Philadelphia, Division of Oncology, Philadelphia, PA 19104, USA. Foxe@email.chop.edu

Abstract

Anakinra improves the central nervous system manifestations of neonatal-onset multisystem inflammatory disease, which is mediated by IL-1beta oversecretion. The cerebrospinal fluid (CSF) penetration of the IL-1 receptor antagonist anakinra was studied in rhesus monkeys after intravenous doses of 3 and 10 mg/kg. Drug exposure (area under concentration-time curve) in CSF was 0.28% of that in serum. The average CSF concentration at 3 mg/kg was 1.8 ng/mL, which is 30-fold higher than endogenous CSF levels of IL-1Ra. The CSF penetration was not dose-dependent, indicating that the CSF penetration was not saturated in the 3 to 10 mg/kg dose range.

PMID:
20421138
PMCID:
PMC2887614
DOI:
10.1016/j.jneuroim.2010.03.022
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center